Biotech News

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

Zentalis (ZNTL)ZentalisCompany update

Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that members of the management team will participate in the following upcoming investor conferences:

Related news

Zentalis

Cell-Cycle Oncology Company Zentalis Pharmaceuticals develops azenosertib, an oral inhibitor of WEE1, a regulator of DNA-damage checkpoints and cell-cycle progression. Cyclin E1-Positive Ovarian Cancer The lead program targets platinum-resistant ovarian cancers with Cyclin E1 expression, where replication stress may create heightened...

Recent company news

Stock data

Close
1.36 USD
Market cap
281.19M USD
Exchange
NASDAQ
Sector
Small Molecule Drugs
Location
United States